GENENTECH, INC.
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2013-06-05
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01868893
- Locations
- πΊπΈ
Clearview Cancer Institute, Huntsville, Alabama, United States
πΊπΈCancer Center of Central Conn., Southington, Connecticut, United States
πΊπΈPeachtree Hematology & Oncology Consultants, Pc, Atlanta, Georgia, United States
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-05-24
- Last Posted Date
- 2017-11-28
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT01862081
- Locations
- πΊπΈ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈTexas Oncology, P.A; Baylor Sammons Cancer Center, Dallas, Texas, United States
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
- Conditions
- Interventions
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 138
- Registration Number
- NCT01846416
- Locations
- πΊπΈ
Ohio State Uni Hospital, Columbus, Ohio, United States
πΊπΈPenn Presbyterian Medical Center; Abramson Cancer Center, Philadelphia, Pennsylvania, United States
πΊπΈUniversity of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-04-04
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT01823835
- Locations
- π³π±
VU MEDISCH CENTRUM; Dept. of Medical Oncology, Amsterdam, Netherlands
πΊπΈVanderbilt University Medical Center, Nashville, Tennessee, United States
πΊπΈDana Farber Cancer Institute, Boston, Massachusetts, United States
A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2013-03-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT01814709
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
- Conditions
- First Posted Date
- 2013-03-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 662
- Registration Number
- NCT01804140
A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib
- Conditions
- Interventions
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT01772290
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
- Conditions
- Interventions
- First Posted Date
- 2012-12-20
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT01753167
- Locations
- π«π·
Hopital Pellegrin-CHU de Bordeaux; Service de Neurologie, Bordeaux, France
π«π·Hopital Necker, Paris, France
π«π·Hopital Rangueil; Gastro Enterologie Et Nutrition, Toulouse, France
The Management of Schizophrenia in Clinical Practice (MOSAIC)
- Conditions
- First Posted Date
- 2012-12-10
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 557
- Registration Number
- NCT01746134
A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer
- First Posted Date
- 2012-12-04
- Last Posted Date
- 2017-04-24
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 183
- Registration Number
- NCT01740336
- Locations
- πΊπΈ
Pacific Cancer Medical Center, Anaheim, California, United States
πΊπΈHelen & Harry Gray Cancer Center-Hartford Hospital-CCD PRIME; Research, Hartford, Connecticut, United States
πΊπΈOncology Specialists, S.C., Park Ridge, Illinois, United States